Medifast Statistics
Total Valuation
Medifast has a market cap or net worth of $110.46 million. The enterprise value is -$46.12 million.
Important Dates
The next estimated earnings date is Monday, April 27, 2026, after market close.
| Earnings Date | Apr 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Medifast has 10.99 million shares outstanding. The number of shares has increased by 0.16% in one year.
| Current Share Class | 10.31M |
| Shares Outstanding | 10.99M |
| Shares Change (YoY) | +0.16% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.00% |
| Owned by Institutions (%) | 71.20% |
| Float | 9.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.29 |
| Forward PS | 0.36 |
| PB Ratio | 0.52 |
| P/TBV Ratio | 0.56 |
| P/FCF Ratio | 88.44 |
| P/OCF Ratio | 16.10 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.69, with a Debt / Equity ratio of 0.05.
| Current Ratio | 4.69 |
| Quick Ratio | 3.89 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 2.17 |
| Debt / FCF | 8.56 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -9.13% and return on invested capital (ROIC) is -29.67%.
| Return on Equity (ROE) | -9.13% |
| Return on Assets (ROA) | -3.34% |
| Return on Invested Capital (ROIC) | -29.67% |
| Return on Capital Employed (ROCE) | -6.93% |
| Weighted Average Cost of Capital (WACC) | 6.80% |
| Revenue Per Employee | $1.02M |
| Profits Per Employee | -$49,137 |
| Employee Count | 380 |
| Asset Turnover | 1.45 |
| Inventory Turnover | 3.53 |
Taxes
In the past 12 months, Medifast has paid $13.03 million in taxes.
| Income Tax | 13.03M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.91% in the last 52 weeks. The beta is 0.58, so Medifast's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | -27.91% |
| 50-Day Moving Average | 10.97 |
| 200-Day Moving Average | 12.50 |
| Relative Strength Index (RSI) | 40.25 |
| Average Volume (20 Days) | 303,317 |
Short Selling Information
The latest short interest is 2.02 million, so 18.39% of the outstanding shares have been sold short.
| Short Interest | 2.02M |
| Short Previous Month | 2.01M |
| Short % of Shares Out | 18.39% |
| Short % of Float | 21.92% |
| Short Ratio (days to cover) | 7.71 |
Income Statement
In the last 12 months, Medifast had revenue of $385.79 million and -$18.67 million in losses. Loss per share was -$1.70.
| Revenue | 385.79M |
| Gross Profit | 275.19M |
| Operating Income | -14.21M |
| Pretax Income | -5.64M |
| Net Income | -18.67M |
| EBITDA | 29,000 |
| EBIT | -14.21M |
| Loss Per Share | -$1.70 |
Full Income StatementBalance Sheet
The company has $167.27 million in cash and $10.69 million in debt, with a net cash position of $156.58 million or $14.25 per share.
| Cash & Cash Equivalents | 167.27M |
| Total Debt | 10.69M |
| Net Cash | 156.58M |
| Net Cash Per Share | $14.25 |
| Equity (Book Value) | 198.92M |
| Book Value Per Share | 19.29 |
| Working Capital | 158.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $6.86 million and capital expenditures -$5.61 million, giving a free cash flow of $1.25 million.
| Operating Cash Flow | 6.86M |
| Capital Expenditures | -5.61M |
| Free Cash Flow | 1.25M |
| FCF Per Share | $0.11 |
Full Cash Flow StatementMargins
Gross margin is 71.33%, with operating and profit margins of -3.68% and -4.84%.
| Gross Margin | 71.33% |
| Operating Margin | -3.68% |
| Pretax Margin | -1.46% |
| Profit Margin | -4.84% |
| EBITDA Margin | 0.01% |
| EBIT Margin | -3.68% |
| FCF Margin | 0.32% |
Dividends & Yields
Medifast does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.16% |
| Shareholder Yield | -0.16% |
| Earnings Yield | -16.90% |
| FCF Yield | 1.13% |
Dividend DetailsAnalyst Forecast
The average price target for Medifast is $12.00, which is 19.40% higher than the current price. The consensus rating is "Hold".
| Price Target | $12.00 |
| Price Target Difference | 19.40% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Medifast has an Altman Z-Score of 4.75 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.75 |
| Piotroski F-Score | 3 |
